AUTHOR=Tardiveau Claire , Monneret Guillaume , Lukaszewicz Anne-Claire , Cheynet Valérie , Cerrato Elisabeth , Imhoff Katia , Peronnet Estelle , Bodinier Maxime , Kreitmann Louis , Blein Sophie , Llitjos Jean-François , Conti Filippo , Gossez Morgane , Buisson Marielle , Yonis Hodane , Cour Martin , Argaud Laurent , Delignette Marie-Charlotte , Wallet Florent , Dailler Frederic , Monard Céline , Brengel-Pesce Karen , Venet Fabienne , the RICO study group TITLE=A 9-mRNA signature measured from whole blood by a prototype PCR panel predicts 28-day mortality upon admission of critically ill COVID-19 patients JOURNAL=Frontiers in Immunology VOLUME=13 YEAR=2022 URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1022750 DOI=10.3389/fimmu.2022.1022750 ISSN=1664-3224 ABSTRACT=

Immune responses affiliated with COVID-19 severity have been characterized and associated with deleterious outcomes. These approaches were mainly based on research tools not usable in routine clinical practice at the bedside. We observed that a multiplex transcriptomic panel prototype termed Immune Profiling Panel (IPP) could capture the dysregulation of immune responses of ICU COVID-19 patients at admission. Nine transcripts were associated with mortality in univariate analysis and this 9-mRNA signature remained significantly associated with mortality in a multivariate analysis that included age, SOFA and Charlson scores. Using a machine learning model with these 9 mRNA, we could predict the 28-day survival status with an Area Under the Receiver Operating Curve (AUROC) of 0.764. Interestingly, adding patients’ age to the model resulted in increased performance to predict the 28-day mortality (AUROC reaching 0.839). This prototype IPP demonstrated that such a tool, upon clinical/analytical validation and clearance by regulatory agencies could be used in clinical routine settings to quickly identify patients with higher risk of death requiring thus early aggressive intensive care.